Abstract
No public abstract is available from the verified source records.
Yi-Fan Mai, Chun-Kuang Tsai, Wei-Sheng Chen
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies
10.1136/annrheumdis-2019-216114 · 2020
Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)
10.1007/s10067-022-06391-w · 2023
Cryoglobulinemic vasculitis in primary Sjögren’s syndrome: clinical presentation, association with lymphoma and comparison with hepatitis C-related disease
10.1016/j.semarthrit.2020.07.013 · 2020
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
10.1016/s2352-3026(17)30078-9 · 2017
Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia
10.2217/fon-2017-0574 · 2018
Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)
10.1093/annonc/mdw685 · 2017
Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remission
10.1093/rheumatology/keaf324 · 2025
Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission
10.3389/fmed.2025.1583401 · 2025
No additional external references are available.